845305-83-1

Usage

Uses

Used in Pharmaceutical Industry:
4-(Piperidin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester is used as a synthetic intermediate for the development of new pharmaceutical compounds. Its unique structure and properties make it a promising candidate for the synthesis of drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(Piperidin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester serves as a key building block for the creation of complex organic molecules. Its reactivity and functional groups allow for various chemical transformations, facilitating the synthesis of a wide range of organic compounds.
Used in Material Development:
4-(Piperidin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester is utilized in the development of new materials, thanks to its potential to form stable and functional polymers or other composites. Its incorporation into material systems could lead to advancements in areas such as coatings, adhesives, or even specialized materials for specific industries.
Used in Research and Testing:
This chemical compound is also used in research and testing to explore its biological activity and potential applications in various fields. Further studies are necessary to fully understand its properties and to unlock its full potential in practical applications.

Upstream product

• 1172626-94-6 C₂₂H₃₄N₂O₃ 
• 845305-82-0 1-benzyl-4-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)pyridin-1-ium bromide 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 626-64-2 pyridin-4-ol 
• 308386-35-8 1,1-dimethylethyl 4-(4'-pyridinyloxy)-1-piperidinecarboxylate 

Downstream Products

• 845306-84-5 4-{4-[(1-tert-butoxycarbonyl-4-piperidinyl)oxy]-1-piperidinyl}benzonitrile 
• 1138448-35-7 C₂₂H₃₁F₂N₃O₄ 
• 1138448-37-9 C₂₂H₃₁F₃N₂O₃ 

Relevant academic research and scientific papers

BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY

Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE

The disclosure provides BRD9 bifunctional compounds of Formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, to their preparation, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases and disorders mediated by a bromodomain-containing protein, such as bromodoma in-containing protein 9 (BRD9)

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES

The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

3-HYDROXY-N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)PYRROLIDINE-1-CARBOXAMIDE DERIVATIVES

The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions compris

OXYPIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to novel Oxypiperidine Derivatives, pharmaceutical compositions comprising the Oxypiperidine Derivatives and the use of the Oxypiperidine Derivatives for treating or preventing treating allergy, an allergy-induced airway resp

A practical synthesis of differentially protected 4,4′-dipiperidinyl ethers: Novel ligands of pharmaceutical interest

An efficient four-step synthesis (requiring no purification) of Boc-protected 4,4′-dipiperidinyl ethers is described. Georg Thieme Verlag Stuttgart.

A two-step procedure for the preparation of mono-protected bis-N-heterocyclic alkyl ether systems

A two-step convenient sequence for the synthesis of previously inaccessible mono-Boc-protected bis-N-heterocyclic alkyl substituted ether derivatives 4 is described. Mitsunobu protocol was applied to the preparation of pyridinyl ether precursor 5. The reduction of the electron rich pyridinyl system 5 has been achieved catalytically using the combination of PtO2-H2SO4 or PtO2-pTsOH under a hydrogen atmosphere maintained by a gas balloon at ambient temperature.

Novel compounds useful for bradykinin B1 receptor antagonism

Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor.

SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS

The present invention relates to novel piperidine ether derivatives having affinity for the histamine H3 receptor, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.